Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS).

[1]  Y. Kamei,et al.  Increased Adiponectin Secretion by Highly Purified Eicosapentaenoic Acid in Rodent Models of Obesity and Human Obese Subjects , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[2]  Y. Matsuzawa,et al.  Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis , 2007, The Lancet.

[3]  Y. Ouchi,et al.  Prevalence of metabolic syndrome in the general Japanese population in 2000. , 2006, Journal of atherosclerosis and thrombosis.

[4]  Y. Kokubo,et al.  Intake of Fish and n3 Fatty Acids and Risk of Coronary Heart Disease Among Japanese: The Japan Public Health Center-Based (JPHC) Study Cohort I , 2006, Circulation.

[5]  Paul Zimmet,et al.  The metabolic syndrome—a new worldwide definition , 2005, The Lancet.

[6]  S. Takagi,et al.  Incidence of insulin resistance in obese subjects in a rural Japanese population: The Tanno and Sobetsu study , 2005, Diabetes, obesity & metabolism.

[7]  J. Fruchart,et al.  Atherogenic Lipoprotein Particles in Atherosclerosis , 2004, Circulation.

[8]  David E Newby,et al.  Omega 3 fatty acids and cardiovascular disease-- fishing for a natural treatment , 2003 .

[9]  H. Origasa,et al.  Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia: rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS). , 2003, American heart journal.

[10]  Paul M Ridker,et al.  High-sensitivity C-reactive protein and cardiovascular risk: rationale for screening and primary prevention. , 2003, The American journal of cardiology.

[11]  P. Calder,et al.  Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial , 2003, The Lancet.

[12]  W. Harris,et al.  Cardiovascular disease and long-chain omega-3 fatty acids , 2003, Current opinion in lipidology.

[13]  Jukka T Salonen,et al.  The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. , 2002, JAMA.

[14]  S. Kihara,et al.  Adiponectin Reduces Atherosclerosis in Apolipoprotein E-Deficient Mice , 2002, Circulation.

[15]  T. Yano,et al.  Changes in aspects such as the collagenous fiber density and foam cell size of atherosclerotic lesions composed of foam cells, smooth muscle cells and fibrous components in rabbits caused by all-cis-5, 8, 11, 14, 17-icosapentaenoic acid. , 2002, Journal of atherosclerosis and thrombosis.

[16]  J. Manson,et al.  Fish and omega-3 fatty acid intake and risk of coronary heart disease in women. , 2002, JAMA.

[17]  H. Lodish,et al.  Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[18]  Ames,et al.  PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA , 2000 .

[19]  ichard,et al.  FISH CONSUMPTION AND THE 30-YEAR RISK OF FATAL MYOCARDIAL INFARCTION , 2000 .

[20]  GISSI-Prevenzione Investigators,et al.  Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial , 1999, The Lancet.

[21]  Roberto Marchioli,et al.  Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. , 1999 .

[22]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[23]  G. Reaven.  Banting lecture 1988 , 1997 .

[24]  J. Manson,et al.  Fish consumption and cardiovascular disease in the physicians' health study: a prospective study. , 1995, American journal of epidemiology.

[25]  T Nakamura,et al.  Contribution of visceral fat accumulation to the development of coronary artery disease in non-obese men. , 1994, Atherosclerosis.

[26]  R. DeFronzo,et al.  Insulin Resistance: A Multifaceted Syndrome Responsible for NIDDM, Obesity, Hypertension, Dyslipidemia, and Atherosclerotic Cardiovascular Disease , 1991, Diabetes Care.

[27]  P. Elwood,et al.  EFFECTS OF CHANGES IN FAT, FISH, AND FIBRE INTAKES ON DEATH AND MYOCARDIAL REINFARCTION: DIET AND REINFARCTION TRIAL (DART) , 1989, The Lancet.

[28]  N. Kaplan.  The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. , 1989, Archives of internal medicine.

[29]  G. Reaven.  Role of Insulin Resistance in Human Disease , 1988, Diabetes.

[30]  G. Reaven.  Banting lecture 1988. Role of insulin resistance in human disease. , 1988, Diabetes.

[31]  H. Sewell,et al.  CYTOCHROME P-450 IMMUNOLOCALISATION IN HUMAN LIVER , 1986, The Lancet.

[32]  T. Terano,et al.  Clinical and epidemiological studies of eicosapentaenoic acid (EPA) in Japan. , 1986, Progress in lipid research.

[33]  J. Vane,et al.  EICOSAPENTAENOIC ACID AND PREVENTION OF THROMBOSIS AND ATHEROSCLEROSIS? , 1978, The Lancet.

[34]  U. Essers,et al.  CANCER RESEARCH: SOME FORWARD STEPS. , 1965, Lancet.